85%Confidence
0Views
FDASource
2026-03-05Date
Summary
McKesson faces a Class I recall for UDENYCA due to temperature abuse, indicating potential supply chain quality control failures. This could impact Accord BioPharma's reputation and lead to increased regulatory scrutiny for McKesson's distribution practices.
Actionable: Monitor McKesson's stock for potential short-term volatility and review any holdings in Accord BioPharma for risk exposure.
AI Confidence: 85%
Data Points
firmMcKesson
classificationClass I
statusOngoing
distributionNationwide in the USA
productUDENYCA, pegfilgrastim-cbqv injection, 6 mg/0.6mL Single Dose Prefilled Syringe, Rx only, Manufactured by Accord BioPharma, Inc., 8041 Arco Corporate
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now